673 related articles for article (PubMed ID: 33718121)
1. "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.
Malik A; Thanekar U; Amarachintha S; Mourya R; Nalluri S; Bondoc A; Shivakumar P
Front Oncol; 2020; 10():627701. PubMed ID: 33718121
[TBL] [Abstract][Full Text] [Related]
2. Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities.
Shah DD; Dave BP; Patel PA; Chorawala MR; Patel VN; Shah PA; Patel MP
Med Oncol; 2023 Jan; 40(2):84. PubMed ID: 36680649
[TBL] [Abstract][Full Text] [Related]
3. The immunology of hepatocellular carcinoma.
Ringelhan M; Pfister D; O'Connor T; Pikarsky E; Heikenwalder M
Nat Immunol; 2018 Mar; 19(3):222-232. PubMed ID: 29379119
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.
Chen C; Wang Z; Ding Y; Qin Y
Front Immunol; 2023; 14():1133308. PubMed ID: 36845131
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
Liu X; Qin S
Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
[TBL] [Abstract][Full Text] [Related]
6. New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Khanam A; Kottilil S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613878
[TBL] [Abstract][Full Text] [Related]
7. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
O'Rourke JM; Sagar VM; Shah T; Shetty S
World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
[TBL] [Abstract][Full Text] [Related]
8. Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis.
Lin Q; Tang Z; Qin Y; Deng X; Wei C; Liu F; Pan X; Liu D; Zhan T; Fang M
PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011906. PubMed ID: 38285640
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
10. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
11. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Moeini A; Torrecilla S; Tovar V; Montironi C; Andreu-Oller C; Peix J; Higuera M; Pfister D; Ramadori P; Pinyol R; Solé M; Heikenwälder M; Friedman SL; Sia D; Llovet JM
Gastroenterology; 2019 Nov; 157(5):1383-1397.e11. PubMed ID: 31344396
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
13. CHD4/NuRD complex regulates complement gene expression and correlates with CD8 T cell infiltration in human hepatocellular carcinoma.
Shao S; Cao H; Wang Z; Zhou D; Wu C; Wang S; Xia D; Zhang D
Clin Epigenetics; 2020 Feb; 12(1):31. PubMed ID: 32070428
[TBL] [Abstract][Full Text] [Related]
14. An emerging research: the role of hepatocellular carcinoma-derived exosomal circRNAs in the immune microenvironment.
Xu HZ; Lin XY; Xu YX; Xue HB; Lin S; Xu TW
Front Immunol; 2023; 14():1227150. PubMed ID: 37753074
[TBL] [Abstract][Full Text] [Related]
15. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
Koo SY; Park EJ; Lee CW
Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
[TBL] [Abstract][Full Text] [Related]
16. State of CD8
Zhong X; Lv M; Ma M; Huang Q; Hu R; Li J; Yi J; Sun J; Zhou X
Biomed Pharmacother; 2023 Sep; 165():115131. PubMed ID: 37429231
[TBL] [Abstract][Full Text] [Related]
17. Bibliometric study of immunotherapy for hepatocellular carcinoma.
Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
[TBL] [Abstract][Full Text] [Related]
18. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells.
Gao X; Zuo S
Clin Exp Med; 2023 Oct; 23(6):1881-1899. PubMed ID: 36773210
[TBL] [Abstract][Full Text] [Related]
19. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
20. Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma.
Zaki MYW; Fathi AM; Samir S; Eldafashi N; William KY; Nazmy MH; Fathy M; Gill US; Shetty S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
